CA2490022A1 - A platform for transdermal formulations (ptf) - Google Patents
A platform for transdermal formulations (ptf) Download PDFInfo
- Publication number
- CA2490022A1 CA2490022A1 CA002490022A CA2490022A CA2490022A1 CA 2490022 A1 CA2490022 A1 CA 2490022A1 CA 002490022 A CA002490022 A CA 002490022A CA 2490022 A CA2490022 A CA 2490022A CA 2490022 A1 CA2490022 A1 CA 2490022A1
- Authority
- CA
- Canada
- Prior art keywords
- composition according
- patch
- ptf
- oily emulsion
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 37
- 238000009472 formulation Methods 0.000 title description 6
- 239000000839 emulsion Substances 0.000 claims abstract description 33
- 235000015097 nutrients Nutrition 0.000 claims abstract description 11
- 150000001875 compounds Chemical class 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims description 37
- 229940079593 drug Drugs 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- 239000000787 lecithin Substances 0.000 claims description 14
- 235000010445 lecithin Nutrition 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 150000008040 ionic compounds Chemical group 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 229940016409 methylsulfonylmethane Drugs 0.000 claims description 12
- 229920001184 polypeptide Polymers 0.000 claims description 12
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims description 12
- 239000003833 bile salt Substances 0.000 claims description 10
- 235000012000 cholesterol Nutrition 0.000 claims description 10
- 241001465754 Metazoa Species 0.000 claims description 7
- 229940093761 bile salts Drugs 0.000 claims description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- 150000002898 organic sulfur compounds Chemical class 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 4
- 229940125687 antiparasitic agent Drugs 0.000 claims description 4
- 239000003096 antiparasitic agent Substances 0.000 claims description 4
- 244000144972 livestock Species 0.000 claims description 3
- 238000002483 medication Methods 0.000 claims description 3
- JEUAKJVLHISJDY-UHFFFAOYSA-N 2,3-dimethylthiolane 1,1-dioxide Chemical compound CC1CCS(=O)(=O)C1C JEUAKJVLHISJDY-UHFFFAOYSA-N 0.000 claims description 2
- WKFQMDFSDQFAIC-UHFFFAOYSA-N 2,4-dimethylthiolane 1,1-dioxide Chemical compound CC1CC(C)S(=O)(=O)C1 WKFQMDFSDQFAIC-UHFFFAOYSA-N 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 230000000507 anthelmentic effect Effects 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 229910021645 metal ion Inorganic materials 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000000829 suppository Substances 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 64
- 102000004877 Insulin Human genes 0.000 description 32
- 108090001061 Insulin Proteins 0.000 description 32
- 229940125396 insulin Drugs 0.000 description 32
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 24
- 239000008103 glucose Substances 0.000 description 24
- NQPDXQQQCQDHHW-UHFFFAOYSA-N 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole Chemical compound ClC=1C=C2NC(SC)=NC2=CC=1OC1=CC=CC(Cl)=C1Cl NQPDXQQQCQDHHW-UHFFFAOYSA-N 0.000 description 16
- 229960000323 triclabendazole Drugs 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 230000037317 transdermal delivery Effects 0.000 description 13
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 11
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 10
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 244000309466 calf Species 0.000 description 9
- 229960002418 ivermectin Drugs 0.000 description 9
- 102000055006 Calcitonin Human genes 0.000 description 8
- 108060001064 Calcitonin Proteins 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 229960004015 calcitonin Drugs 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 6
- 229960001680 ibuprofen Drugs 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 5
- 102000051325 Glucagon Human genes 0.000 description 5
- 108060003199 Glucagon Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 5
- 229960004666 glucagon Drugs 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 239000000813 peptide hormone Substances 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000002218 hypoglycaemic effect Effects 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960003773 calcitonin (salmon synthetic) Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 235000003891 ferrous sulphate Nutrition 0.000 description 3
- 239000011790 ferrous sulphate Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 108010068072 salmon calcitonin Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000013271 transdermal drug delivery Methods 0.000 description 3
- 241000238876 Acari Species 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000242711 Fasciola hepatica Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000037374 absorbed through the skin Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- XXDVUVPHJGZWQC-QHTZZOMLSA-L (2s)-2-amino-5-hydroxy-5-oxopentanoate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)[C@@H](N)CCC(O)=O.[O-]C(=O)[C@@H](N)CCC(O)=O XXDVUVPHJGZWQC-QHTZZOMLSA-L 0.000 description 1
- MZCACYLMMMXSKC-UHFFFAOYSA-N 32 amino acid peptide Chemical compound C=1C=CC=CC=1CC(C(=O)NC(CC=1C2=CC=CC=C2NC=1)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CCC(N)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCCNC(N)=N)NC(=O)C(CCCNC(N)=N)NC(=O)C(CCSC)NC(=O)C(CCCCN)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCCN)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(NC(=O)C(CCC(O)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C1N(CCC1)C(=O)C1NCCC1)C(C)O)CC1=CC=CC=C1 MZCACYLMMMXSKC-UHFFFAOYSA-N 0.000 description 1
- 101800003158 5 kDa peptide Proteins 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 102000017631 Calcitonin-like Human genes 0.000 description 1
- 108050005865 Calcitonin-like Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- MBYXEBXZARTUSS-QLWBXOBMSA-N Emetamine Natural products O(C)c1c(OC)cc2c(c(C[C@@H]3[C@H](CC)CN4[C@H](c5c(cc(OC)c(OC)c5)CC4)C3)ncc2)c1 MBYXEBXZARTUSS-QLWBXOBMSA-N 0.000 description 1
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000006968 Helminthiasis Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 102000003982 Parathyroid hormone Human genes 0.000 description 1
- 102100036893 Parathyroid hormone Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- ATTZFSUZZUNHBP-UHFFFAOYSA-N Piperonyl sulfoxide Chemical compound CCCCCCCCS(=O)C(C)CC1=CC=C2OCOC2=C1 ATTZFSUZZUNHBP-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- AUVVAXYIELKVAI-UHFFFAOYSA-N SJ000285215 Natural products N1CCC2=CC(OC)=C(OC)C=C2C1CC1CC2C3=CC(OC)=C(OC)C=C3CCN2CC1CC AUVVAXYIELKVAI-UHFFFAOYSA-N 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000242541 Trematoda Species 0.000 description 1
- 241000869417 Trematodes Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- AUVVAXYIELKVAI-CKBKHPSWSA-N emetine Chemical compound N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@@H]1CC AUVVAXYIELKVAI-CKBKHPSWSA-N 0.000 description 1
- 229960002694 emetine Drugs 0.000 description 1
- AUVVAXYIELKVAI-UWBTVBNJSA-N emetine Natural products N1CCC2=CC(OC)=C(OC)C=C2[C@H]1C[C@H]1C[C@H]2C3=CC(OC)=C(OC)C=C3CCN2C[C@H]1CC AUVVAXYIELKVAI-UWBTVBNJSA-N 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000006275 fascioliasis Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 235000002332 ferrous fumarate Nutrition 0.000 description 1
- 239000011773 ferrous fumarate Substances 0.000 description 1
- 229960000225 ferrous fumarate Drugs 0.000 description 1
- 229910001448 ferrous ion Inorganic materials 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 244000000013 helminth Species 0.000 description 1
- 229940045644 human calcitonin Drugs 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 206010033794 paragonimiasis Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 208000014837 parasitic helminthiasis infectious disease Diseases 0.000 description 1
- 230000000590 parasiticidal effect Effects 0.000 description 1
- 239000002297 parasiticide Substances 0.000 description 1
- 239000000199 parathyroid hormone Substances 0.000 description 1
- 229960001319 parathyroid hormone Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 210000004258 portal system Anatomy 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- -1 see: CharZg Chemical compound 0.000 description 1
- 238000011450 sequencing therapy Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
- 229960005460 teriparatide Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10228680A DE10228680A1 (de) | 2002-06-27 | 2002-06-27 | Grundlage für transdermale Formulierungen (PTF) |
| DE10228680.9 | 2002-06-27 | ||
| PCT/IB2003/003467 WO2004002444A2 (en) | 2002-06-27 | 2003-06-21 | A platform for transdermal formulations (ptf) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2490022A1 true CA2490022A1 (en) | 2004-01-08 |
Family
ID=29761469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002490022A Abandoned CA2490022A1 (en) | 2002-06-27 | 2003-06-21 | A platform for transdermal formulations (ptf) |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20050118241A1 (enExample) |
| EP (1) | EP1515706A2 (enExample) |
| JP (1) | JP2005535635A (enExample) |
| KR (1) | KR20050027995A (enExample) |
| CN (1) | CN1665492A (enExample) |
| AR (1) | AR040287A1 (enExample) |
| AU (1) | AU2003252459A1 (enExample) |
| CA (1) | CA2490022A1 (enExample) |
| DE (1) | DE10228680A1 (enExample) |
| MX (1) | MXPA04012732A (enExample) |
| MY (1) | MY157852A (enExample) |
| TW (1) | TW200500093A (enExample) |
| WO (1) | WO2004002444A2 (enExample) |
| ZA (1) | ZA200500710B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7033998B2 (en) * | 2003-04-11 | 2006-04-25 | All Natural Fmg, Inc. | Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
| US7396819B2 (en) * | 2003-08-08 | 2008-07-08 | Virbac Corporation | Anthelmintic formulations |
| WO2005094210A2 (en) * | 2004-03-12 | 2005-10-13 | The Hartz Mountain Corporation | Multi-action anthelmintic formulations |
| US10042980B2 (en) | 2005-11-17 | 2018-08-07 | Gearbox Llc | Providing assistance related to health |
| US10296720B2 (en) | 2005-11-30 | 2019-05-21 | Gearbox Llc | Computational systems and methods related to nutraceuticals |
| US20110145009A1 (en) * | 2005-11-30 | 2011-06-16 | Jung Edward K Y | Methods and systems related to transmission of nutraceutical associatd information |
| WO2010132562A2 (en) * | 2009-05-12 | 2010-11-18 | Ohio University | Transdermal delivery of metformin |
| ES2693687T3 (es) | 2009-06-05 | 2018-12-13 | Joan M. Caron | Compuestos y composiciones para uso en el tratamiento del cáncer |
| US20150297725A1 (en) * | 2012-07-30 | 2015-10-22 | Rutgers, The State University Of New Jersey | Cochleates made with soy phosphatidylserine |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4878892A (en) * | 1987-02-10 | 1989-11-07 | Drug Delivery Systems Inc. | Electrolytic transdermal delivery of polypeptides |
| FR2616333A1 (fr) * | 1987-06-12 | 1988-12-16 | Cird | Procede d'ionophorese pour administrer une substance dissoute ou partiellement dissoute, par voie percutanee ou perungueale et dispositif correspondant |
| JPS63316737A (ja) * | 1987-06-19 | 1988-12-26 | Toyo Jozo Co Ltd | 経鼻投与用医薬組成物 |
| IT1223343B (it) * | 1987-11-03 | 1990-09-19 | Also Lab Sas | Formulazioni farmaceutiche per somministrazione transdermica |
| US5332577A (en) * | 1988-12-27 | 1994-07-26 | Dermamed | Transdermal administration to humans and animals |
| EP0429842B1 (en) * | 1989-10-27 | 1996-08-28 | Korea Research Institute Of Chemical Technology | Device for the transdermal administration of protein or peptide drug |
| US5073539A (en) * | 1990-01-22 | 1991-12-17 | Ciba-Geigy Corporation | Transdermal administration of zwitterionic drugs |
| NZ243721A (en) * | 1991-07-26 | 1994-11-25 | Smithkline Beecham Corp | Self-emulsifying microemulsion comprising water soluble drug, high hlb surfactant and a lipophilic phase containing fatty acid triglyceride and a low hlb surfactant |
| FR2687321B1 (fr) * | 1992-02-14 | 1999-04-16 | Elf Aquitaine | Dispositif d'ionophorese pour l'administration transcutanee d'une quantite totale donnee d'un principe actif a un sujet. |
| US5894021A (en) * | 1994-09-30 | 1999-04-13 | Kabushiki Kaisya Advance | Iontophoretic transdermal drug-delivery interface and skin treatment agent and treatment method using the same |
| US5707641A (en) * | 1994-10-13 | 1998-01-13 | Pharmaderm Research & Development Ltd. | Formulations comprising therapeutically-active proteins or polypeptides |
| US5759445A (en) * | 1995-05-24 | 1998-06-02 | Matsushita Electric Industrial Co., Ltd. | Lipid-dispersed solution and process for producing the same |
| US6183758B1 (en) * | 1998-01-29 | 2001-02-06 | Highland Laboratories, Inc. | Phytochemicals, nutrients & medication absorption &/or treatment |
| PT1094781E (pt) * | 1998-07-07 | 2008-10-08 | Transdermal Technologies Inc | Composições para administração transdérmica rápida e não irritante de agentes farmacologicamente activos e métodos para formulação de tais composições e sua administração |
| TR200103188T2 (tr) * | 1999-05-07 | 2002-04-22 | Pharmasol Gmbh | Sıvı ve katı lipit karışımları temelli lipid parçacıklar. |
| US6309663B1 (en) * | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
-
2002
- 2002-06-27 DE DE10228680A patent/DE10228680A1/de not_active Withdrawn
-
2003
- 2003-06-21 JP JP2004517161A patent/JP2005535635A/ja active Pending
- 2003-06-21 MX MXPA04012732A patent/MXPA04012732A/es not_active Application Discontinuation
- 2003-06-21 KR KR1020047021277A patent/KR20050027995A/ko not_active Withdrawn
- 2003-06-21 EP EP03761748A patent/EP1515706A2/en not_active Withdrawn
- 2003-06-21 AU AU2003252459A patent/AU2003252459A1/en not_active Abandoned
- 2003-06-21 CN CN038151030A patent/CN1665492A/zh active Pending
- 2003-06-21 US US10/511,463 patent/US20050118241A1/en not_active Abandoned
- 2003-06-21 CA CA002490022A patent/CA2490022A1/en not_active Abandoned
- 2003-06-21 WO PCT/IB2003/003467 patent/WO2004002444A2/en not_active Ceased
- 2003-06-23 TW TW092116951A patent/TW200500093A/zh unknown
- 2003-06-24 MY MYPI20032357A patent/MY157852A/en unknown
- 2003-06-27 AR ARP030102324A patent/AR040287A1/es not_active Application Discontinuation
-
2005
- 2005-01-03 ZA ZA200500710A patent/ZA200500710B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200500093A (en) | 2005-01-01 |
| ZA200500710B (en) | 2005-09-05 |
| MY157852A (en) | 2016-07-29 |
| AU2003252459A1 (en) | 2004-01-19 |
| WO2004002444A3 (en) | 2004-03-11 |
| CN1665492A (zh) | 2005-09-07 |
| AR040287A1 (es) | 2005-03-23 |
| MXPA04012732A (es) | 2005-11-17 |
| JP2005535635A (ja) | 2005-11-24 |
| KR20050027995A (ko) | 2005-03-21 |
| WO2004002444A2 (en) | 2004-01-08 |
| EP1515706A2 (en) | 2005-03-23 |
| DE10228680A1 (de) | 2004-01-22 |
| US20050118241A1 (en) | 2005-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6274166B1 (en) | Transdermal delivery system | |
| AU2003238862B9 (en) | Formulations for amylin agonist peptides | |
| TWI685348B (zh) | 速效胰島素組合物 | |
| US5574006A (en) | Nasally administrable peptide compositions on hydroxyapatite carriers | |
| US7033998B2 (en) | Alcohol-free transdermal insulin composition and processes for manufacture and use thereof | |
| US20050118241A1 (en) | Platform for transdermal formulations (ptf) | |
| Fransson et al. | Transdermal absorption of a liposomeencapsulated formulation of lidocaine following topical administration in cats | |
| RU2543635C2 (ru) | Способ и фармацевтические композиции для лечения постпрандиальной гипергликемии диабета ii типа введением через слизистую ротовой полости | |
| US7291591B2 (en) | Alcohol-free transdermal insulin composition | |
| SK9062000A3 (en) | Transmucosal formulations of levosimendan | |
| EP1079801A1 (en) | A pharmaceutical formulation for nasal administration | |
| KR100466757B1 (ko) | 생체에 펩티드성 약물을 유입시키기 위한 국소 제제 | |
| JPS63303931A (ja) | 経鼻投与用成長ホルモン放出活性物質製剤 | |
| US20020164366A1 (en) | Transdermal delivery system | |
| Zimmer et al. | Noninvasive drug delivery | |
| JPS6045161B2 (ja) | 熱傷の治療剤 | |
| JP2734554B2 (ja) | インスリン様成長因子ｉの点鼻用液剤 | |
| JPH0242027A (ja) | 経粘膜吸収促進剤及びこれを用いた経鼻投与剤 | |
| JPH01501708A (ja) | アミノ酸の経鼻投与 | |
| JPS6237017B2 (enExample) | ||
| KR930002093B1 (ko) | 단백질 의약품의 경구투여용 조성물 | |
| JPH06154287A (ja) | 治療装置 | |
| JPH06154319A (ja) | 治療装置 | |
| Dugger III et al. | Immediate-Immediate Release (I2R) Lingual or Buccal Spray Formulations for Transmucosal Delivery of Drug Substances | |
| Higgins | Insulin delivery: will injections always be necessary? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |